<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072432</url>
  </required_header>
  <id_info>
    <org_study_id>REN-002</org_study_id>
    <nct_id>NCT04072432</nct_id>
  </id_info>
  <brief_title>A Study With Iron Sucrose in Healthy Volunteers and Chronic Kidney Disease Stage 3-4 Subjects</brief_title>
  <official_title>A Phase 1b Dose-escalating Study With Iron Sucrose (FeS), in Healthy Volunteers and Subjects With Chronic Kidney Disease Stage 3-4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renibus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renibus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b dose-escalating study evaluating the pharmacodynamic effect of FeS in healthy
      volunteers and chronic kidney disease stage 3-4 subjects. Biomarkers will be used as
      surrogate measures of protective activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b single-center, dose-escalating study to evaluate the pharmacodynamic
      effect of FeS in healthy volunteers and in subjects with stage 3-4 CKD. The following
      biomarkers will be used as surrogate measures of protective activity: Haptoglobin, Ferritin,
      Hemopexin, IL-10, and Heme Oxygenase-1. Additionally, the P21 biomarker will be monitored at
      various points of the study.

      Screening data will be reviewed to determine subject eligibility. Subjects who meet all
      inclusion criteria and none of the exclusion criteria are eligible to be enrolled into the
      study.

      The study is designed as follows:

        -  A screening period with baseline evaluations for study eligibility.

        -  If subjects meet eligibility criteria, they will receive FeS by IV infusion on study
           day1.

        -  Subjects will stay in the clinic for the initial 24 hours after administration of FeS
           and will be discharged at the end of Day 2 if no safety issues appear.

        -  The study will be dose-escalating in 3 groups of 6 subjects consisting of 3 healthy
           volunteers and 3 subjects with stage 3-4 chronic kidney disease, evaluating doses of 120
           mg FeS, 240 mg FeS and 360 mg FeS.

        -  Subjects will be followed for 8 days after the dose of FeS. Response biomarkers will be
           assessed at baseline and 2,4, 8, 12, 18, 24, 48, 72, 96 and 168 hours after study drug
           administration.

        -  Total study duration will be 8 days for each subject, in addition to a screening period
           of up to 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2018</start_date>
  <completion_date type="Actual">August 26, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Ferritin Measurement Taken at 168 Hours</measure>
    <time_frame>7 days</time_frame>
    <description>Effect of FeS on ferritin measurement of the urine after 168 hours</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Kidney Failure, Acute</condition>
  <arm_group>
    <arm_group_label>120 mg FeS IV infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 120 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>240 mg FeS infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 240 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>360 mg FeS Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 360 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron sucrose</intervention_name>
    <description>single FeS infusion</description>
    <arm_group_label>120 mg FeS IV infusion</arm_group_label>
    <arm_group_label>240 mg FeS infusion</arm_group_label>
    <arm_group_label>360 mg FeS Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Volunteers

          1. Male and female subjects age 18 to 80 years (inclusive, at time of ICF).

          2. Body weight &lt;125 kg.

          3. Able and willing to comply with all study procedures.

          4. Female subjects must be either post-menopausal for at least 1 year or surgically
             sterile (tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3
             months, or if of childbearing potential, have a negative pregnancy test and agree to
             use dual methods of contraception, or abstain from sexual activity from Screening
             until 8 days after study drug administration.

        Male subjects with female partners of childbearing potential must agree to use a highly
        effective method of contraception from screening until 8 days after study drug
        administration. All fertile men with female partners of childbearing potential should be
        instructed to contact the Investigator immediately if they suspect their partner might be
        pregnant (e.g., missed or late menstrual period) at any time during study participation.

        CKD Subjects

          1. Male and female subjects age 18 to 80 years (inclusive, at time of ICF).

          2. Body weight &lt;125 kg.

          3. Able and willing to comply with all study procedures.

          4. Female subjects must be either post-menopausal for at least 1 year or surgically
             sterile (tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3
             months, or if of childbearing potential, have a negative pregnancy test and agree to
             use dual methods of contraception, or abstain from sexual activity from Screening
             until 8 days after study drug administration.

             Male subjects with female partners of childbearing potential must agree to use a
             highly effective method of contraception from screening until 8 days after study drug
             administration. All fertile men with female partners of childbearing potential should
             be instructed to contact the Investigator immediately if they suspect their partner
             might be pregnant (e.g., missed or late menstrual period) at any time during study
             participation.

          5. CKD as determined by estimated glomerular filtration rate (GFR) between 15-59 ml/min
             as estimated using the CKD-EPI equation (CKD class 3-4).

        Exclusion Criteria:

        Healthy Volunteers

          1. History of malignancy except carcinoma in situ in the cervix, early stage prostate
             cancer or non-melanoma skin cancers.

          2. Use of investigational drugs or participation in another clinical trial within 30 days
             or 5 half-lives prior to screening, whichever is longer.

          3. Serum ferritin &gt; 500 ng/ml or who have received IV iron within 28 days of screening.

          4. Women who are pregnant, breastfeeding, or planning to become pregnant while
             participating in the study.

          5. Any significant acute or chronic diseases.

          6. Regular use of drugs of abuse and/or positive findings on urinary drug screening.

          7. Current tobacco use and/or positive findings on urinary cotinine screening.

          8. Subjects who are severely physically or mentally incapacitated and who, in the opinion
             of investigator, are unable to perform the subjects' tasks associated with the
             protocol.

          9. Presence of any condition which, in the opinion of the investigator, places the
             subject at undue risk or potentially jeopardizes the quality of the data to be
             generated.

         10. Known hypersensitivity or previous anaphylaxis to FeS.

        CKD Subjects

          1. History of malignancy except carcinoma in situ in the cervix, early stage prostate
             cancer or non-melanoma skin cancers.

          2. Use of investigational drugs or participation in another clinical trial within 30 days
             or 5 half-lives prior to screening, whichever is longer.

          3. Serum ferritin &gt; 500 ng/ml or who have received IV iron within 28 days of screening,
             or currently being treated with oral iron.

          4. Women who are pregnant, breastfeeding, or planning to become pregnant while
             participating in the study.

          5. Regular use of drugs of abuse and/or positive findings on urinary drug screening.

          6. Current tobacco use and/or positive findings on urinary cotinine screening.

          7. Subjects who are severely physically or mentally incapacitated and who, in the opinion
             of investigator, are unable to perform the subjects' tasks associated with the
             protocol.

          8. Presence of any condition which, in the opinion of the investigator, places the
             subject at undue risk or potentially jeopardizes the quality of the data to be
             generated.

          9. Known hypersensitivity or previous anaphylaxis to FeS or to components thereof.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <results_first_submitted>January 31, 2020</results_first_submitted>
  <results_first_submitted_qc>February 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2020</results_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04072432/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04072432/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>120 mg FeS IV Infusion</title>
          <description>A single dose of 120 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
        </group>
        <group group_id="P2">
          <title>240 mg FeS Infusion</title>
          <description>A single dose of 240 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
        </group>
        <group group_id="P3">
          <title>360 mg FeS Infusion</title>
          <description>A single dose of 360 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>120 mg FeS IV Infusion</title>
          <description>A single dose of 120 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
        </group>
        <group group_id="B2">
          <title>240 mg FeS Infusion</title>
          <description>A single dose of 240 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
        </group>
        <group group_id="B3">
          <title>360 mg FeS Infusion</title>
          <description>A single dose of 360 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="51" upper_limit="72"/>
                    <measurement group_id="B2" value="64" lower_limit="31" upper_limit="71"/>
                    <measurement group_id="B3" value="64" lower_limit="50" upper_limit="78"/>
                    <measurement group_id="B4" value="61" lower_limit="31" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Ferritin Measurement Taken at 168 Hours</title>
        <description>Effect of FeS on ferritin measurement of the urine after 168 hours</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>120 mg FeS IV Infusion</title>
            <description>A single dose of 120 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
          </group>
          <group group_id="O2">
            <title>240 mg FeS Infusion</title>
            <description>A single dose of 240 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
          </group>
          <group group_id="O3">
            <title>360 mg FeS Infusion</title>
            <description>A single dose of 360 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Ferritin Measurement Taken at 168 Hours</title>
          <description>Effect of FeS on ferritin measurement of the urine after 168 hours</description>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.542" spread="77.1031"/>
                    <measurement group_id="O2" value="198.613" spread="133.0021"/>
                    <measurement group_id="O3" value="188.646" spread="26.1344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analyses of variance for repeated measures (ANOVA)</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>p values were corrected for multiple comparisons by the Bonferroni test if required</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA for repeated measures</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>120 mg FeS IV Infusion</title>
          <description>A single dose of 120 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
        </group>
        <group group_id="E2">
          <title>240 mg FeS Infusion</title>
          <description>A single dose of 240 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
        </group>
        <group group_id="E3">
          <title>360 mg FeS Infusion</title>
          <description>A single dose of 360 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
Iron sucrose: single FeS infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Donald J Keyser, Chief Operating Officer</name_or_title>
      <organization>Renibus Therapeutics</organization>
      <phone>18178756991</phone>
      <email>jkeyser@renibus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

